Navigation Links
Immucor Announces Fiscal Fourth Quarter Results
Date:7/23/2009

mission, and related customer class action lawsuits; the Company's inability to protect its intellectual property or its infringement of the intellectual property of others; lower than expected market acceptance of the molecular immunohematology products; the unexpected application of different accounting rules; general economic conditions; and adverse developments with respect to the operation or performance of the Company, its products and its affiliates or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this Press Release can be found in the Company's Risk Factor disclosures in its Form 10-K for the year ended May 31, 2009. Immucor assumes no obligation to update any forward-looking statements. 

                                      IMMUCOR, INC.
                       CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                     (unaudited, in thousands except per share data)
                                     Three Months Ended      Year Ended
                                     May 31,   May 31,   May 31,   May 31,
                                      2009      2008      2009      2008
    NET SALES                        $79,041   $68,614  $300,547  $261,199
    COST OF SALES                     23,802    19,221    84,536    75,710
    GROSS PROFIT                      55,239    49,393   216,011   185,489

    OPERATING EXPENSES
      Research and development         3,144     1,443    10,698     6,454
      Selling and marketing            9,654     9,951    39,191    32,970
      Distribution                     3,383     3,183    13,708    11,394
      General and administrative       8,813     6,540    31,717    25,925
      Restructuring expense                -        -          -       646
      Amortization expense and other   1,072        96     3,739       357
        Total operating expenses      26,066    21,
'/>"/>
SOURCE  Immucor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 

Related medicine news :

1. Immucor Appoints Chief Operating Officer
2. Immucor Submits 10-Day Response to FDA; Establishes Product Surveillance and Improvement Department
3. Immucor to Announce Fiscal Fourth Quarter Financial Results on Thursday, July 23, 2009
4. Immucor Announces Fiscal Year 2010 Guidance
5. Immucor to Announce Fiscal 2010 Guidance on Monday, June 1, 2009
6. Immucor to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
7. Immucor Receives Subpoena From Department of Justice
8. Immucor Announces Fiscal Third Quarter Results
9. Immucor Announces New Vice President, Operations
10. Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance
11. Immucor Closes BioArray Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... OAK BROOK, Ill. (May 23, 2013) Aortic arch ... a strong independent predictor of disease of the vessels ... new study published in the June issue the journal ... the aortic arch provides functional information about vessel compliance ... disease down the road," said Kevin S. King, M.D., ...
(Date:5/23/2013)... May 23, 2013 During pregnancy both ... are affected by medical treatments, especially medication. In ... Journal of Medicine prompted the FDA to warn about ... birth defects such as persistent pulmonary hypertension and other ... serotonin reuptake inhibitor (SSRI) drugs. SSRI antidepressants are ...
(Date:5/23/2013)... York (PRWEB) May 23, 2013 Maintaining ... today launches its Summer Health Campaign. Kicking off in ... to offering a luxury bed for everyone and to ... overall health and well-being. , May is Better Sleep ... by the Better Sleep Council due to the Centers ...
(Date:5/23/2013)... To kick off barbecue season, fire up the grill ... calories with simple tips from Retrofit weight loss . ... summer. , “The powerful heat of the grill can be ... are not mindful of your selections, it can be as ... Amy Margulies. , Margulies advises clients to choose healthy options ...
(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...
Breaking Medicine News(10 mins):Health News:MRI-based measurement helps predict vascular disease in the brain 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3Health News:DUXIANA®, Quality Bed Innovator, Celebrates Better Sleep Month and Launches Summer Health Campaign 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 2Health News:Fire It Up! Master Calories at the Grill with Retrofit Weight Loss 3Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3
... WASHINGTON , Feb. 5 In response ... today, the American Veterinary Medical Association (AVMA) is reaffirming its ... help maintain and improve the health of U.S. livestock. , ... creating a new strategy for animal disease traceability. This comes ...
... says benefits still outweigh dangers , FRIDAY, Feb. 5 ... controversial multiple sclerosis drug Tysabri, the U.S. Food and ... a new warning on the drug,s label. , In ... FDA warned that the risk of developing progressive multifocal ...
... , TROY, Mich. , ... technology (IT) and web products and services company serving U.S. ... M. Hanley to the newly formed position of vice ... http://www.newscom.com/cgi-bin/prnh/20100205/DE50447 ) , "I am delighted to have Colleen join ...
... , , ... Diseases (HTDS; http://www.htdsmedical.com/ ) brings attention to a certain previously released ... , Dec 15, 2009 January 12,2010 , and ... for the company as all of these events are now starting to ...
... unhealthy cycle, some moms-to-be may need special support, researchers ... whose mothers were depressed during pregnancy are at increased ... suggests. , The British researchers also found that women ... years are more likely to become depressed during pregnancy, ...
... , MILWAUKEE , ... Daytona Bike Week, hundreds of female motorcycle enthusiasts and Harley-Davidson ... Association (MDA) and their efforts to find a cure for ... MDA and the Motor Company will host the 3rd Annual ...
Cached Medicine News:Health News:AVMA Calls for Stronger Animal Disease Traceability System 2Health News:More Doses of MS Drug Raise Risk of Brain Infection 2Health News:More Doses of MS Drug Raise Risk of Brain Infection 3Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 2Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 2Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 3Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 4Health News:Hard to Treat Diseases (HTDS) Update On Various Business Developments Evaluations and Proposals 5Health News:Women Riders to Rev for a Cure at Daytona Bike Week 2Health News:Women Riders to Rev for a Cure at Daytona Bike Week 3
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
(Date:5/23/2013)... May 23, 2013  MedVantx, Inc., the company that ... channel announced today the Company has completed a major ... in pharmaceutical products and the upgrade of its systems ... facilities in its specialty home delivery pharmacy in ... leading pharmaceutical manufacturers, physicians, health systems and payors novel ...
(Date:5/23/2013)... 23, 2013 InspireMD, Inc. ... leader in embolic protection stents, today announced new ... ST Elevation Reperfusion) trial demonstrating that the MGuard ... drug eluting stents in all-cause mortality in ST ... the trial were presented at the InspireMD STEMI ...
Breaking Medicine Technology:MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... May 18, 2011 Ovid, part of ... the delivery of customizable electronic research information for the medical, scientific, ... OvidMD , the first clinical ... provides quick answers to clinical questions based on relevant full-text content ...
... FRANCISCO, May 18, 2011 Bayer HealthCare Pharmaceuticals, Inc. and ... that data evaluating the use of Nexavar® (sorafenib) tablets will ... Meeting of the American Society of Clinical Oncology (ASCO), June ... committed to researching the potential utility of sorafenib, and the ...
Cached Medicine Technology:Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 2Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 3Ovid Announces its First Clinical Tool, OvidMD, Designed for Physicians and Other Clinicians 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 2Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 3Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 5Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 6Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 7
... Positionable Penile Prosthesis,The ... prosthesis is made of ... core strength that gives ... most: ease of positioning, ...
... The AMS 700 Series is an advanced ... in the abdomen, a pump placed in the ... the corpora cavernosa. It closely simulates the look ... standard for innovative penile implant technology, the AMS ...
... advanced three-part inflatable prosthesis consisting of a reservoir ... the scrotum and a pair of cylinders inserted ... look and performance of a natural erection. The ... AMS 700 Series now features the new Tactile ...
... Freedom leg bags are part of ... versatile line of leg bags, kits, ... varied needs of our customers. These ... sizes, and constructed of 100% latex-free ...
Medicine Products: